# Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

> **NCT00460486** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 330 (—)

## Conditions studied

- Encephalitis, Tick-Borne

## Interventions

- **BIOLOGICAL:** Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

## Key facts

- **NCT ID:** NCT00460486
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 330 (—)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460486, "Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00460486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*